The FDA Is Finally Considering a New Sunscreen Ingredient. Here’s What to Know

For decades, Americans have struggled to find reliable and effective sunscreens that don’t leave a greasy residue or turn their skin an unnatural shade of white. Despite the well-documented risks of skin cancer and premature aging caused by excessive UV exposure, the US market has been stuck in a rut, relying on outdated ingredients that barely provide adequate protection.

The FDA’s recent announcement that it is considering approving a new sunscreen ingredient called bemotrizinol marks a significant step forward. This broad-spectrum blocker of both UVA and UVB rays has been used successfully in Europe and other parts of the world for years, where it has become an industry standard.

Sunscreen as we know it today is a relatively recent innovation, dating back to the 1970s when the government began regulating sunscreens as drugs. Since then, scientists have made significant progress in understanding the risks associated with UV exposure and developing more effective ways to protect against it.

However, the development of new sunscreen ingredients has been slow-going in the US due to the high bar for proving safety set by the FDA. No new UV-blocking ingredient has been approved in 25 years, creating a regulatory environment that is both challenging and uncertain for manufacturers. This has led some companies to drop out of the approval process altogether.

Bemotrizinol’s case is different, though. Its unique size and properties require substantially less safety testing than other ingredients, making it a more feasible option for US manufacturers. With DSM-Firmenich’s guidance through the approval system, this ingredient may finally be on the cusp of breaking into the US market.

The approval of bemotrizinol could open up new possibilities for sunscreen formulations that don’t rely on outdated ingredients like avobenzone. This is particularly important given the growing body of evidence linking avobenzone and other similar chemicals to potential health risks.

Beyond its practical benefits, the approval of bemotrizinol also represents a shift in the regulatory landscape around sunscreen development. It suggests that the FDA is taking seriously the need for more comprehensive safety testing and greater transparency in the industry. This is a welcome change, especially given the alarming rates of skin cancer and other UV-related health problems plaguing our society.

The approval of bemotrizinol raises questions about our priorities as a society. What does it say that it has taken so long to catch up with international standards in sunscreen technology? And what other areas of consumer product regulation might benefit from a similar shake-up?

Ultimately, the approval of bemotrizinol is not just a victory for consumers looking for better sunscreens; it’s also a testament to the power of science and regulatory reform. It shows that even in the face of entrenched interests and bureaucratic red tape, progress can be made when we demand more from our policymakers.

The approval of bemotrizinol could soon provide consumers with a safer and more effective way to protect their skin from the sun. As this development unfolds, it’s essential to keep an eye on its broader implications for consumer product regulation, public health, and the environment as a whole.